All News

Article

EULAR 2023: Featured Industry Presentations

Jack Cush, MD May 30, 2023

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR

Article

Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway

Jack Cush, MD May 25, 2023

Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA).

Article

NSAID Prescribing Decreasing

Jack Cush, MD May 24, 2023

Multinational metanalyses of data between 1989 and 2022 shows that NSAID prescriptions have decreased over time, and differs according to geographical locations.

Article

Allergic Drug-Induced Arthritis (5.19.2023)

Jack Cush, MD May 19, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Article

Peresolimab's Potential in Rheumatoid Arthritis

Jack Cush, MD May 18, 2023

Peresolimab is a humanized IgG1 monoclonal antibody that acts as a programmed cell death protein 1 (PD-1) agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active rheumatoid arthritis (RA).

New benefit/risk outlook 👀 on ORAL surveillance 2 subgrps: 🟢RA w/ no previous Hx of atherosclerotic CV dis = TOFA at least as good as TNFi AND risk of MACE is comparable 🛑RA w/ HxASCVD = efficacy TOFA = TNFi AND > risk of MACE https://t.co/VOxNQSoyY4 OP0043 #EULAR23 @Rheumnow https://t.co/m98eSMG03U

EULAR Abstract Archive

Leiden arthritis clinic: 1000+ pts w/ RA & high BMI associated w/ < MRI-detected osteitis at dis onset but NOT synovitis RA w/ overweight/obesity 25% < MRI-detected erosive progression at 2 yrs More marked in ACPA+ pts Is leptin the missing link? 🤓 OP0039 #EULAR23 @Rheumnow https://t.co/RRSV9VlRtn

Biosimilar vs originator: as switches loom in the US, once again it’s really hard to say we see any differences in drug survival for our RA patients These data from forced switching in BC, Canada are just like the others - biosimilars are business as usual. POS0567 #EULAR2023 https://t.co/Ebl1hTM4qE

Ongoing work to #classify #inflammatory #arthritis in Pts using #check #point #inhibitors. A 1st step to study the etiology of immune changes from these life prolonging medications #EULAR2023 @RheumNow https://t.co/Bv1q8IphqF

https://twitter.com/drdavidliew/status/1663889739307704324

Can #machine #learning replace #rheumatologists? OP0190 #EULAR23 #Machine learning can help determine who will develop #rheumatoidarthritis in Pts with #arthralgia but the real study could be ask #clinician the #probability of RA and do #AI and see comparative accuracy @RheumNow

When does RA get complicated? Many things can burden our patients, making their RA difficult to treat #EULAR2023 @RheumNow https://t.co/FM1UCNbmKr

TAS5315, BTK inhibitor, studied in 91 MTX refractory RA pts. Wk 12 ACR20 resp was 79% on TAS5315 vs 60% PBO (p=0.053); ACR50 (33 vs 13%) not signif. Adverse event equal betw grps, but 9 pts had bleeding on TAS5315 https://t.co/XYS0XRMJar https://t.co/ntGtahFf4T

https://bit.ly/3IGs5bO

Systematic review proves Keystones 60%/40%/20% response rule in biologic-naive #RA. 21 RCTs 1999-2017; For bio-naïve pts the ACR20/50/70 was 61.4%/37.8%/ 18.8%. For Bio-IR it was 48.5%/27.3%/12.9%- roughly 10pts lower. https://t.co/Xr3QEw278J https://t.co/OAfNghXlvB

https://bit.ly/3oulDOq

UK Biobank cohort study (n=361,952) assessed BMI effects on rheumatic Dz risk. Higher BMI incr odds of RA (IRR=1.52), OA (IRR=1.49), PsA (IRR=1.80), gout (1.73), SpA(1.34); more pronounced in women for both gout and psoriatic arthropathy https://t.co/eLeeShSSv1 https://t.co/IjWF2EPqOR

https://bit.ly/45Dvfqz

A claims cohort comparison of #RA pts with H.zoster (n 1 866 ) and pts without HZ (38,846). RA+/HZ+ pts had significantly greater Hospitalizations, emergency visits (esp <30d post HZ Dx; adj IRR hosp=3.4; ED=3.7) and higher Total HC costs https://t.co/89GLUK93dO https://t.co/9jweduoBHw

https://bit.ly/3WKEOQz

Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk

Join us for the final Tuesday Night Rheumatology of May. This webinar will feature highlights from these lectures followed by live audience Q & A: Methotrexate Use: 50 Yr. Perspective Myths vs Reality in RA Biosimilars - Back on the Agenda https://t.co/0OenWkXarV https://t.co/yUHwslkZ9o

https://bit.ly/3MDz9Hl

Peresolimab's Potential in Rheumatoid Arthritis Peresolimab is a humanized IgG1 monoclonal antibody that acts as a PD-1 agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active RA. https://t.co/tBAC2vO31f https://t.co/pAknsSnnNT

https://bit.ly/43bS9nk

Swedish registry review of #MTX initiation in early #PsA vs #RA (n 3642each). 2 years after MTX start, 71% of PsA vs 76% of patients with RA remained on MTX & the majority (66%/60%) had not started another DMARD, or a biologic (77%/74%) https://t.co/nTJO04sn65 https://t.co/gLjKzj2c74

https://bit.ly/3Il8UUI

Study of 481 incident RA: - no risk of RA w/ tea, alcohol & sugar-soft drinks - Incr RA risk seen w/ coffee [≥4 vs ≤1cup, HR=1.24;p=0.04] & diet drinks [HR=1.66;never-smokers] - Reduced RA risk w/ mod EtOH (ever-smokers;HR=0.63) & wine (seropos RA) https://t.co/RQFpxXUT11 https://t.co/ew2imYMLnJ

https://bit.ly/3M458QG

Topics

All News

EULAR 2023: Featured Industry Presentations

Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway

NSAID Prescribing Decreasing

Allergic Drug-Induced Arthritis (5.19.2023)

Peresolimab's Potential in Rheumatoid Arthritis

Do you get our email newsletter?